Triple

T4784989
Position Surface form Disambiguated ID Type / Status
Subject mAb114 E106453 entity
Predicate sponsor P67 FINISHED
Object Ridgeback Biotherapeutics
Ridgeback Biotherapeutics is a biotechnology company focused on developing antiviral and immunotherapy treatments for serious infectious diseases, including Ebola and COVID-19.
 E468969 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Ridgeback Biotherapeutics | Statement: [mAb114, sponsor, Ridgeback Biotherapeutics]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: Ridgeback Biotherapeutics
Context triple: [mAb114, sponsor, Ridgeback Biotherapeutics]
  • A. Insitro
    Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
  • B. Regeneron Pharmaceuticals
    Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
  • C. Vir Biotechnology
    Vir Biotechnology is a clinical-stage immunology company focused on developing treatments and prophylactics for serious infectious diseases using antibody, T cell, and other immune-based technologies.
  • D. Kymab
    Kymab is a biotechnology company based in Cambridge, UK, focused on developing antibody-based therapeutics using its proprietary transgenic mouse platforms.
  • E. Elan Pharmaceuticals
    Elan Pharmaceuticals was a biotechnology company best known for developing therapies for neurological and autoimmune diseases, including the multiple sclerosis drug Tysabri.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Ridgeback Biotherapeutics
Triple: [mAb114, sponsor, Ridgeback Biotherapeutics]
Generated description
Ridgeback Biotherapeutics is a biotechnology company focused on developing antiviral and immunotherapy treatments for serious infectious diseases, including Ebola and COVID-19.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: Ridgeback Biotherapeutics
Target entity description: Ridgeback Biotherapeutics is a biotechnology company focused on developing antiviral and immunotherapy treatments for serious infectious diseases, including Ebola and COVID-19.
  • A. Insitro
    Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
  • B. Regeneron Pharmaceuticals
    Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
  • C. Vir Biotechnology
    Vir Biotechnology is a clinical-stage immunology company focused on developing treatments and prophylactics for serious infectious diseases using antibody, T cell, and other immune-based technologies.
  • D. Kymab
    Kymab is a biotechnology company based in Cambridge, UK, focused on developing antibody-based therapeutics using its proprietary transgenic mouse platforms.
  • E. Elan Pharmaceuticals
    Elan Pharmaceuticals was a biotechnology company best known for developing therapies for neurological and autoimmune diseases, including the multiple sclerosis drug Tysabri.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69bd43f4a9588190bf73e20bc27c03cc completed March 20, 2026, 12:56 p.m.
NER Named-entity recognition batch_69bd65ae49ec81908f16248d22d1155f completed March 20, 2026, 3:20 p.m.
NED1 Entity disambiguation (via context triple) batch_69be43dbdec88190817845e7930a18f6 completed March 21, 2026, 7:08 a.m.
NEDg Description generation batch_69be447c21d48190ab57c8761e733ff4 completed March 21, 2026, 7:10 a.m.
NED2 Entity disambiguation (via description) batch_69be45f5ebec8190b62c428b465d1bd9 completed March 21, 2026, 7:17 a.m.
Created at: March 20, 2026, 1:22 p.m.